PRLI
Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer (PRLI)
This prospective study evaluates the efficacy and safety of hypofractionated proton therapy in the treatment of medium- and low-risk prostate cancer.